STAR

Strides Pharma Science Limited
Micro-capPharma

What the six lenses say about STAR — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹1178.8
2026-09-08
VWAP · 1Y anchor
₹959
+22.9% from VWAP
P/E · TTM
19.5×
TTM EPS ₹60.3
52-week range
98%
position low→high
RSI(14)
78
momentum

Own sector index

Pharma
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How STAR’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
6.5
avg conviction decile
Leadership
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD660

The actual numbers

Price vs VWAP (1y)+22.9%
EMA trend stackMixed
Price vs 200-EMA+19.5%
Price vs 50-EMA+14.2%
RSI(14)78
RS vs Nifty 500 · 3M+12.8%
RS vs sector · 3M+6.7%
52-week range98%
Volume vs 30d avg0.92×
Volume vs 60d avg1.37×
ATR(14) · volatility52.9
Bollinger width · vol contraction0.193
FundamentalD747

The actual numbers

Return on equity (ROE)18.5%
Operating margin17.4%
Net margin11.8%
Revenue growth · YoY+4.9%
EPS growth · YoY+66.5%
Debt / equity0.57×

Full 8-quarter history in the financials table below.

ValuationD642

The actual numbers

P/E (TTM)19.5×
TTM EPS₹60.3
52-week range98%
CatalystD639

The actual numbers

Earnings & momentum38
Capital actions14
Governance91

Every filing in the corporate-announcements panel below.

FlowD750

The actual numbers

Promoter holding27.9%
Delivery · 30d avg44.9%
Up/down-day asymmetry-3.6pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D6 + D7 ) ÷ 2 = 6.5(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · High
59
Conviction score 59/100 · avg-decile strength 6.5/10

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+11.7pp
+16.3pp
+21.7pp
+14.4pp
+39.0pp
+37.8pp
Nifty 500
Broad-market baseline
+11.7pp
+16.3pp
+20.6pp
+12.8pp
+33.3pp
+32.5pp
Sector
Own-sector index
+17.8pp
+6.7pp
+20.2pp
+11.7pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

STAR daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
1178.80+119.20

Relative strength

RS vs baseline · rebased to 100

STAR ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
102.28+10.73

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)1,0881,2011,1541,1901,1201,2211,1951,323
↳ change QoQ+10.4%-3.9%+3.1%-5.9%+9.0%-2.1%+10.7%
EBITDA (₹cr)226260213218218231236240
EBITDA margin20.8%21.7%18.5%18.3%19.5%18.9%19.8%18.1%
PAT (₹cr)68949086106132208129
↳ change QoQ+37.1%-3.9%-4.5%+23.3%+24.5%+57.6%-38.0%
Net margin6.3%7.8%7.8%7.2%9.5%10.8%17.4%9.8%
EPS (₹)7.6410.149.568.9110.8013.8421.9313.77
D/E
YoY growth · Mar '26Revenue +11.2% YoYPAT +50.0% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 19 Aug '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 3 Aug '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 31 Jul '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 31 Jul '26
    HIGHearnings
    Outcome of Board Meeting

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 24 Jul '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 21 Jul '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jul '26
    LOWgovernance
    Sale or disposal

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jun '26
    LOWgovernance
    Sale or disposal

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 27 Jun '26
    MEDIUMcapital
    Press Release

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 8 Jun '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    General Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 28 May '26
    LOWgovernance
    Analysts/Institutional Investor Meet/Con. Call Updates

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds STAR

Mutual funds holding STAR (5)

FundWeightAUM ₹crGrade
Quant Small Cap Gr1.09%34,069
Bandhan Small Cap Reg Gr0.59%31,103
Quant Multi Cap Gr1.89%7,717
Quant Healthcare Reg Gr2.64%397
Samco Multi Cap Reg Gr0.51%228

ETFs holding STAR (0)

No tracked ETF holds STAR ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma